NO20091064L - Antistoffer mot IL-17A - Google Patents

Antistoffer mot IL-17A

Info

Publication number
NO20091064L
NO20091064L NO20091064A NO20091064A NO20091064L NO 20091064 L NO20091064 L NO 20091064L NO 20091064 A NO20091064 A NO 20091064A NO 20091064 A NO20091064 A NO 20091064A NO 20091064 L NO20091064 L NO 20091064L
Authority
NO
Norway
Prior art keywords
antibodies
human
modified antibodies
summary modified
modified
Prior art date
Application number
NO20091064A
Other languages
English (en)
Norwegian (no)
Inventor
Leonard G Presta
Edward P Bowman
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20091064L publication Critical patent/NO20091064L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20091064A 2006-08-11 2009-03-10 Antistoffer mot IL-17A NO20091064L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83719706P 2006-08-11 2006-08-11
PCT/US2007/017679 WO2008021156A2 (en) 2006-08-11 2007-08-09 Antibodies to il-17a

Publications (1)

Publication Number Publication Date
NO20091064L true NO20091064L (no) 2009-05-07

Family

ID=38926184

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091064A NO20091064L (no) 2006-08-11 2009-03-10 Antistoffer mot IL-17A

Country Status (18)

Country Link
US (3) US7846443B2 (pt)
EP (1) EP2046835B1 (pt)
JP (2) JP5118699B2 (pt)
KR (1) KR101218484B1 (pt)
CN (1) CN101646690B (pt)
AR (1) AR063683A1 (pt)
AT (1) ATE530578T1 (pt)
AU (1) AU2007284782B2 (pt)
BR (1) BRPI0715917A2 (pt)
CA (1) CA2660463C (pt)
ES (1) ES2373069T3 (pt)
IL (1) IL196968A (pt)
MX (1) MX2009001620A (pt)
NO (1) NO20091064L (pt)
NZ (1) NZ574804A (pt)
PE (1) PE20080739A1 (pt)
WO (1) WO2008021156A2 (pt)
ZA (1) ZA200901402B (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
JP2009534297A (ja) 2006-03-10 2009-09-24 ザイモジェネティクス, インコーポレイテッド Il−17aおよびil−17fの両方に結合する抗体ならびにその使用方法
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
NZ574804A (en) * 2006-08-11 2012-02-24 Schering Corp Antibodies to il-17a
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
MX2009009167A (es) 2007-02-28 2009-09-04 Schering Corp Terapia de combinacion para el tratamiento de trastornos inmunes.
BRPI0813262A2 (pt) * 2007-06-20 2015-04-14 Schering Corp Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a
EP2182943B1 (en) * 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists
GB0807413D0 (en) * 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
KR20110048536A (ko) * 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 il-22, il-17 및 il-1 패밀리 시토킨의 용도
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
CA2737636A1 (en) * 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
US8911722B2 (en) * 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
WO2011044563A2 (en) * 2009-10-10 2011-04-14 The Board Of Trustees Of The Leland Stanford Junior University Il-17 family cytokine compositions and uses
WO2011053763A2 (en) 2009-10-30 2011-05-05 Centocor Ortho Biotech Inc. Il-17a antagonists
WO2011109298A2 (en) 2010-03-02 2011-09-09 Abbott Laboratories Therapeutic dll4 binding proteins
WO2011141823A2 (en) 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2012018767A2 (en) * 2010-08-05 2012-02-09 Anaptysbio, Inc. Antibodies directed against il-17
JP5828902B2 (ja) * 2010-10-29 2015-12-09 イミュノジェン, インコーポレイテッド 非拮抗性egfr結合分子およびその免疫複合体
CA2815277A1 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
PH12013501435B1 (en) 2011-01-14 2019-02-01 UCB Biopharma SRL Antibody molecules which bind il-17a and il-17f
JP2014533954A (ja) 2011-11-21 2014-12-18 イミュノジェン, インコーポレイテッド Egfr抗体細胞傷害性薬物複合体による、egfr療法に耐性である腫瘍の治療方法
AR091116A1 (es) 2012-05-22 2015-01-14 Bristol Myers Squibb Co Anticuerpos biespecificos y sus metodos de uso
CN104936618A (zh) 2012-11-29 2015-09-23 拜尔健康护理有限责任公司 针对活化蛋白c的人源化单克隆抗体及其用途
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
US9862765B2 (en) * 2013-11-18 2018-01-09 Shanghai Hengrui Pharmaceutical Co., Ltd. IL-17A binding agent and uses thereof
CN105916883B (zh) 2014-01-28 2019-12-03 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
US9476066B2 (en) 2014-03-06 2016-10-25 Iogen Corporation Production of products with favourable GHG emission reductions from cellulosic feedstocks
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
RU2021125449A (ru) 2014-10-01 2021-09-16 Медиммьюн Лимитед Антитела к тикагрелору и способы применения
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
GB201500463D0 (en) 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
CN105315371B (zh) 2015-03-05 2018-05-29 北京百特美博生物科技有限公司 抗人il-17单克隆抗体
AU2016229060A1 (en) * 2015-03-09 2017-09-28 The Regents Of The Universtiy Of Michigan Materials and methods for eliciting targeted antibody responses in vivo
AU2016304060B2 (en) 2015-08-03 2022-09-29 Crage Medical Co., Limited Antibody against glypican-3 and application thereof
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
EP3220145A1 (en) * 2016-03-17 2017-09-20 Universiteit Antwerpen Identification of subjects at risk of developing ventilator-associated pneumonia
TN2019000082A1 (en) * 2016-09-14 2020-07-15 Beijing hanmi pharm co ltd Antibody specifically binding to il-17a and functional fragment thereof
CN109206515B (zh) * 2017-07-06 2021-10-12 北京伟峰益民科技有限公司 一种全人源抗人白介素17a抗体及其应用
CN107522783B (zh) * 2017-09-30 2020-07-07 华博生物医药技术(上海)有限公司 一种抗白介素17a的抗体、其制备方法和应用
US20210079087A1 (en) * 2018-03-29 2021-03-18 Remd Biotherapeutics, Inc. Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)
EP3852617B1 (en) 2018-09-20 2025-09-10 SFJ Pharma X, Inc. Use of antibody fragments for reversing ticagrelor activity
AU2019370367A1 (en) 2018-10-30 2021-06-17 Magenta Therapeutics, Inc. Anti-CD45 antibodies and conjugates thereof
TWI825214B (zh) 2018-11-05 2023-12-11 中國大陸商北京韓美藥品有限公司 抗TNFα/抗IL-17A天然抗體結構樣異源二聚體形式雙特異抗體及其製備
CN111303283A (zh) 2018-12-12 2020-06-19 上海君实生物医药科技股份有限公司 抗il-17a抗体及其应用
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト TNFα及びIL-17Aに対する特異性を有する多重特異性抗体、IL-17Aを標的とする抗体、及びそれらの使用方法
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
WO2021018191A1 (zh) 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
CN115746132B (zh) * 2021-09-03 2023-09-08 三优生物医药(上海)有限公司 抗il-17a抗体及其用途
CN114920838B (zh) * 2022-03-25 2023-11-24 南京融捷康生物科技有限公司 一种抗il-17a的单域抗体及其用途
CN116751277A (zh) * 2023-01-10 2023-09-15 武汉爱博泰克生物科技有限公司 利用毕赤酵母表达活性重组人il-17a蛋白的方法
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
GB0312481D0 (en) * 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
EP1983000B1 (en) 2003-11-21 2015-09-02 UCB Biopharma SPRL Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
AU2005241020B2 (en) 2004-05-03 2008-07-10 Merck Sharp & Dohme Corp. Use of IL-17 expression to predict skin inflammation; methods of treatment
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PL1963368T6 (pl) * 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
JP2009534297A (ja) * 2006-03-10 2009-09-24 ザイモジェネティクス, インコーポレイテッド Il−17aおよびil−17fの両方に結合する抗体ならびにその使用方法
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス, インコーポレイテッド Il−17およびil−23アンタゴニストならびにその使用方法
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
NZ574804A (en) 2006-08-11 2012-02-24 Schering Corp Antibodies to il-17a

Also Published As

Publication number Publication date
US20110038878A1 (en) 2011-02-17
KR20090052347A (ko) 2009-05-25
US20110052596A1 (en) 2011-03-03
CA2660463A1 (en) 2008-02-21
MX2009001620A (es) 2009-02-23
CN101646690B (zh) 2013-10-23
ATE530578T1 (de) 2011-11-15
US8753843B2 (en) 2014-06-17
CA2660463C (en) 2013-07-16
CN101646690A (zh) 2010-02-10
AU2007284782B2 (en) 2012-11-15
ES2373069T3 (es) 2012-01-31
AU2007284782A1 (en) 2008-02-21
JP2010500028A (ja) 2010-01-07
KR101218484B1 (ko) 2013-01-04
WO2008021156A2 (en) 2008-02-21
IL196968A (en) 2013-08-29
WO2008021156A3 (en) 2008-07-03
BRPI0715917A2 (pt) 2014-11-25
IL196968A0 (en) 2011-08-01
EP2046835A2 (en) 2009-04-15
US8193319B2 (en) 2012-06-05
US7846443B2 (en) 2010-12-07
JP5118699B2 (ja) 2013-01-16
AR063683A1 (es) 2009-02-11
NZ574804A (en) 2012-02-24
US20090175881A1 (en) 2009-07-09
PE20080739A1 (es) 2008-06-14
JP2013009680A (ja) 2013-01-17
ZA200901402B (en) 2010-02-24
EP2046835B1 (en) 2011-10-26

Similar Documents

Publication Publication Date Title
CY2025024I1 (el) Βελτιωμενα επιλεκτικα πρωτοϊνιδιων αντισωματα και η χρηση αυτων
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
HUS2100053I1 (hu) Interleukin-13-antitest-készítmény
HUE042689T2 (hu) TGFbéta elleni antitestek
CY2018013I2 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
PT1920065T (pt) Anticorpos anti-alfavbeta6 e suas utilizações
CY2017039I2 (el) Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6
DK2222706T3 (da) Antibodies against human nkg2d and uses thereof
DK1991584T3 (da) Antistoffer mod human IL-22 og anvendelser deraf
EP1964852A4 (en) ANTI-ILT7 ANTIBODY
CR20120210A (es) Proteínas de enlace al antigeno il-23 humanas
RU2426741C3 (ru) Антагонистические антитела к il-17
DK2327423T5 (da) Humane antistoffer mod humant interleukin-22 (IL-22)
DK2032606T3 (da) Antistoffer og immunkonjugater og anvendelser deraf
PL2358756T5 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
IL225372A0 (en) Antibodies directed to her-3 and uses thereof
EP2142214A4 (en) ANTI-IGE ANTIBODY
ATE530578T1 (de) Antikörper gegen il-17a
EP2084185A4 (en) HUMAN ANTIBODIES FOR NEUTRALIZING HUMAN METAPNEUMOVIRUS
EP1912533A4 (en) IMPROVED FOOT STARTER
DE102007021985A8 (de) Fahrpedal-System
EP1765396A4 (en) ANTIBODY
DE502005002101D1 (de) Komposit-membran
DE602006014044D1 (de) Pedalsystem

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP, US

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY

FC2A Withdrawal, rejection or dismissal of laid open patent application